X

Stay Connected

Sign Up for Updates

We are creating a place where we can share ideas, provide the perspective of America's biopharmaceutical companies and, most importantly, listen to you.
Tina Stow

Tina Stow Tina Stow previously served as Vice President of Communications at PhRMA. Prior to joining PhRMA in 2014, she spent more than a dozen years in corporate and agency communications and public affairs roles. A D.C. transplant via North Carolina and Georgia, Tina likes to travel, make the rounds to D.C.’s new restaurants, dote on her rescue labradoodle (Chloe), and complain about winter.

Recent Posts

Welcome news in two high-profile cancer battles

By Tina Stow  |    December 8, 2015
America’s biopharmaceutical companies are proud to be at the forefront of the battle against cancer, working tirelessly to develop innovative approaches for more effective treatments for...   Read More

Week in Review: The Latest from PhRMA

By Tina Stow  |    October 2, 2015
340B Spotlight:  The latest 340B Spotlight explores contract pharmacy arrangements. Learn more about the history of contract pharmacy arrangements and why a policy change in 2010 led to a dramatic...   Read More

New PhRMA Report: 836 medicines and vaccines in development to treat cancers

By Tina Stow  |    September 10, 2015
Almost all of us have fought – or know someone who is fighting – the ruthless disease author Siddhartha Mukherjee termed, “the emperor of all maladies.” Today, cancers remain the second-leading...   Read More

ICYMI – New York Times Editorial Board: Hepatitis C medicines a high value for patients and health care system

By Tina Stow  |    September 4, 2015
In a September 2 editorial, The New York Times Editorial Board concludes that “competitive market forces and hard-nosed bargaining” make “tremendously effective” new hepatitis C medicines not just...   Read More

The drug development and approval process is about much more than the final “okay”

By Tina Stow  |    August 24, 2015
A recent Forbes story not only presents an oddly limited look at the U.S.’s drug development process, it also sends a misleading message to America’s patients and health care professionals. “The...   Read More

ICYMI: Wall Street Journal and Washington Post Say TPP Should Protect Medical Innovation

By Tina Stow  |    August 11, 2015
In case you missed it, The Wall Street Journal and The Washington Post editorialized yesterday on the Trans-Pacific Partnership (TPP) and the importance of reaching a trade deal that protects U.S....   Read More

Fact Check Friday: The Truth about IPR and Biopharmaceutical Patents

By Tina Stow  |    July 31, 2015
Today, we’re pleased to be kicking off our newest Catalyst blog series: Fact Check Friday. We’ll be using this space to separate truth from fiction and set the record straight when the rhetoric...   Read More

Patient Groups, Members of Congress and Other State-Based Stakeholders Agree: Stop the Abuse of Biopharmaceutical Patents

By Tina Stow  |    July 28, 2015
As Congress considers patent legislation known as H.R. 9, the Innovation Act, and S. 1137, the PATENT Act, health care leaders – from patient groups to Members of Congress to trade associations –...   Read More

In Case You Missed It: Progress and Promise in Alzheimer’s Research

By Tina Stow  |    July 15, 2015
PhRMA recently convened a panel of health care experts for a live webcast discussion about the current state of research to treat and care for Alzheimer’s disease. Dr. Bill Chin of PhRMA moderated...   Read More

New PhRMA and Epilepsy Foundation Report: 420 Medicines in Development for Neurological Disorders

By Tina Stow  |    July 13, 2015
It’s hard to imagine, but there are currently more than 50 million Americans – nearly one-sixth of our population – affected by some type of neurological disorder. While some of these are more...   Read More

Search the Catalyst

View Posts by Topic

see all

Subscribe to Email Updates